AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Core other operating income & expense by Quarter
Core other operating income & expense ($M) ($M)
AstraZeneca Core other operating income & expense: $152M in Q2 2026, up 114.1% from a year earlier.
Latest, Q2 2026
152
Period ended Jun 30, 2026
Change on a year earlier
+114.1%
71 in Q2 2025
History
22 quarters
Since Q4 2020
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“|| Other operating income & expense | | 152 | | | – | | | – | | – | | 152 | >2x | >2x”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Reported-to-Core Reconciliation.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca Core other operating income & expense ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-ooi
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.